Table 2.
Outcomes of all-grade adverse events (AEs) and grade ≥ 3 adverse events for triple combination therapy versus control therapy.
| Adverse events | No. studies | RR, 95%CI | P value | Heterogeneity | |
|---|---|---|---|---|---|
| I2 | P value | ||||
| Any events | 4 | 1.01 [0.99, 1.04] | 0.39 | 47% | 0.13 |
| Grade ≥3 | 5 | 1.21 [0.99, 1.49] | 0.07 | 74% | 0.004 |
| Rash | 5 | 1.04 [0.89, 1.22] | 0.58 | 0% | 0.72 |
| Dermatitis acne | 3 | 1.04 [0.71, 1.52] | 0.84 | 5% | 0.35 |
| Pruritus | 4 | 1.20 [0.83, 1.75] | 0.33 | 8% | 0.35 |
| Nausea | 5 | 1.14 [0.82, 1.58] | 0.43 | 52% | 0.08 |
| Diarrhea | 5 | 1.20 [0.86, 1.69] | 0.28 | 66% | 0.02 |
| Vomiting | 4 | 1.20 [0.75, 1.93] | 0.45 | 35% | 0.2 |
| Hypothyroidism | 3 | 2.74 [1.64, 4.56] | 0.0001 | 0% | 0.76 |
| Arthralgia | 5 | 1.57 [1.04, 2.37] | 0.03 | 67% | 0.02 |
| Myalgia | 3 | 1.57 [1.10, 2.24] | 0.01 | 0% | 0.63 |
| ALT increased | 4 | 1.54 [1.12, 2.13] | 0.009 | 8% | 0.35 |
| AST increased | 4 | 1.43 [1.03, 1.98] | 0.03 | 7% | 0.36 |
| Blood ALP increased | 2 | 0.98 [0.67, 1.44] | 0.92 | 0% | 0.43 |
| Chills | 3 | 1.74 [0.81, 3.75] | 0.15 | 85% | 0.001 |
| Fatigue | 5 | 1.13 [0.84, 1.51] | 0.42 | 57% | 0.05 |
| Asthenia | 4 | 1.32 [1.05, 1.67] | 0.02 | 0% | 0.63 |
| Pyrexia | 3 | 1.86 [1.17, 2.95] | 0.009 | 86% | 0.001 |
| Headache | 3 | 2.16 [0.69, 6.76] | 0.18 | 63% | 0.07 |
| Decreased appetite | 2 | 0.95 [0.61, 1.47] | 0.82 | 0% | 0.39 |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.